NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals (NASDAQ:SPPI) announced its quarterly earnings data on Tuesday, March, 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.04. The biotechnology company had revenue of $28.57 million for the quarter, compared to analysts' expectations of $33.18 million. Spectrum Pharmaceuticals had a negative net margin of 70.66% and a negative return on equity of 30.68%. The company's quarterly revenue was down 18.9% compared to the same quarter last year. During the same period last year, the business earned ($0.10) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

4 equities research analysts have issued 1-year target prices for Spectrum Pharmaceuticals' stock. Their forecasts range from $25.00 to $33.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $29.00 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals saw a increase in short interest in April. As of April 13th, there was short interest totalling 11,563,282 shares, an increase of 12.4% from the March 30th total of 10,288,002 shares. Based on an average daily trading volume, of 3,296,568 shares, the days-to-cover ratio is presently 3.5 days. Approximately 12.3% of the company's shares are sold short.

Some companies that are related to Spectrum Pharmaceuticals include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).

Media headlines about SPPI stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Spectrum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include SHROTRIYA RAJESH C MD (5.92%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $17.34.

Spectrum Pharmaceuticals has a market capitalization of $1.90 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]